Prostate cancer is the most commonly diagnosed malignancy in American men. Developing gene therapy for prostate cancer is important, because there is no effective treatment for patients in the advanced stages of this disease. A tissue-specific promoter to transcriptionally target cancer cells is a promising approach for gene therapy of prostate cancer. We previously constructed a prostate tissue-specific promoter based on the proximal promoter and the upstream regulatory sequence of the prostate-specific antigen gene. In the experiments described here, we modified our prostate-specific promoter to drive the A domain of the diphtheria toxin gene (DTA) in a plasmid vector. The plasmid vector can be efficiently transfected into cell lines, using a liposome-mediated transfection method. In the transfected prostate cell line, LNCaP, the DTA gene was actively transcribed, and significant inhibition of protein synthesis and cytopathic effects was observed. However, no pathogenic effects were apparent in the control cell lines. The highly specific and efficient cytopathicity of the DTA gene vector is therefore potentially useful for systemic treatment of patients with metastatic prostate cancer. Cancer Gene Therapy (2000) 7, 991-996
T he most difficult aspect of developing an in vivo approach for human cancer gene therapy is correctly targeting the specific cells of concern. Random delivery of a therapeutic gene damages normal cells in essential organs such as the liver, bone marrow, kidney, and intestine, and may subsequently cause death in treated subjects. 1 Using a tissue-specific promoter to transcriptionally target cancer cells has shown promise. [2] [3] [4] To apply this strategy to prostate cancer gene therapy, a tissue-specific promoter is required. Although several genes have been identified that are specifically expressed in prostate cells, the most extensively studied of these is the prostatespecific antigen (PSA) gene. The PSA protein is exclusively expressed in prostate cells and has been used as a diagnostic indicator of prostate cancer. This specificity of the PSA protein suggests that the promoter of this gene may be useful for tissue-specific expression of a therapeutic gene.
The promoter and the upstream regulatory sequences of the PSA gene have been cloned by a few laboratories, [5] [6] [7] and the tissue specificity has been repeatedly confirmed. However, the cloned sequences in most cases did not show high transcriptional activity. [5] [6] [7] [8] Increased promoter activity for a potent therapeutic gene may be necessary for a gene therapy vector to be effective.
To obtain a promoter with higher activity, we cloned the PSA promoter and upstream regulatory sequences from the cancer cells of a prostate cancer patient with extremely high concentrations of PSA in the blood (ϳ8000-fold higher than normal). Sequence analysis revealed that there were mutations in the promoter and in the upstream regulatory sequences. 9, 10 In our previous studies, we found that the combination of the 550-bp PSA promoter and the 822-bp PSA regulatory sequence together provided the highest levels of activity in driving the expression of transgenes. The activity of the patient-derived sequences was 5-50% of that of the promoter of cytomegalovirus (CMV) early genes (CMV promoter) in the prostate cell line, LNCaP. Using electroporation to transfect the promoter into the cells, the constructed promoter showed ϳ1000-fold tissue specificity.
We hypothesized that with such a tissue-specific promoter to drive a therapeutic gene (such as a toxic gene), we would be able to specifically kill prostate cancer cells. To increase the efficiency of gene delivery, we tested several liposomes for transfection, using vectors containing either firefly luciferase or enhanced green fluorescent protein (EGFP) as a reporter gene. With confirmed tissue specificity and gene expression efficiency of our prostate-specific promoter, we tested the potent cytotoxic diphtheria toxin A (DTA) gene for its utility as a therapeutic gene. Our results demonstrated that the DTA gene, driven by the prostate-specific promoter, efficiently and specifically eradicates prostate cancer cells.
MATERIALS AND METHODS

Plasmid construction
Plasmid constructs containing prostate-specific promoters and the luciferase gene have been described previously. 10 The plasmid containing the CMV promoter and the EGFP gene was purchased from Clontech (Palo Alto, Calif). To create a plasmid containing the PSAR-PCPSA promoter and the EGFP gene, we used a two-step procedure. First, the PSAR-PCPSA promoter was recovered from plasmid PSAR-PCPSAP-Luc, 10 which had been digested by the endonucleases XhoI and BamHI. The promoter was then inserted into the multirestriction endonuclease sites of plasmid pNLDAT1RUEGFP (a gift from Dr. Irvin Chen, University of California Los Angeles School of Medicine), which had been digested with XhoI and BamHI. Plasmid pNLDAT1RUEGFP is structurally similar to plasmid pHRЈ-CMVLacZ, 11 with deletion of the HIV-1 tat gene, the CMV promoter, and the lacZ gene and insertion of the EGFP gene. The plasmid containing the DTA gene, driven by the PSAR-PCPSA promoter, was constructed by replacing the lux gene in plasmid PSAR-PCPSAP-Luc with the DTA gene. Briefly, the DTA gene was recovered by polymerase chain reaction amplification, with plasmid pDT201 (purchased from the American Type Culture Collection (ATCC), Manassas, Va) serving as the template. The sequence coding the N-terminal 193-aa residues was amplified by the primers containing restriction sites for endonucleases HindIII at the 5Ј end and Asp718 at the 3Ј end. The resulting fragment was trimmed by digestion with HindIII and Asp718 before insertion into plasmid PSAR-PCPSAP-Luc, which had been digested by HindIII and Asp 718 .
DNA transfection and androgen stimulation
Liposomes purchased from Life Technologies (Gaithersburg, Md), Promega (Madison, Wis), and Boehringer Mannheim (Indianapolis, Ind) were tested according to the methods suggested by the manufacturers. Cells (5 ϫ 10 4 ) were plated to each well in 24-well plates 16 hours before lipofection. The culture medium was changed 3-16 hours posttransfection, according to the protocol provided by the vendor, and was changed every 2 days thereafter.
Androgen stimulation of transfected cells was performed by adding dihydrotestosterone (DHT) (50 nM) to the culture medium at 1 hour posttransfection.
Tumor cell lines and culture
The prostate cell lines LNCaP and DU145 were purchased from ATCC; the oral tumor cell line Tu139 12 was a gift from Dr. No-Hee Park (University of California Los Angeles School of Dentistry). The other cell lines used have been described previously. 10 Cells were maintained in RPMI 1640 medium with 10% fetal bovine sera from Life Technologies.
Luciferase assays, detection of EGFP-positive cells, and the cytopathic effect of DTA Luciferase assays were performed using the kit from Promega. EGFP-expressing cells were detected under an ultraviolet (UV) microscope purchased from Olympus (Melville, NY).
The pathogenic effect of the DTA vector-transfected cell culture was quantified, using trypsin to remove the cells from the plates, followed by trypan blue staining. The effect was assessed by comparing live cells from the cell culture plates transfected by the DTA vector with the cell culture plates transfected by control vectors.
RESULTS
Tissue-specific expression of the prostate-specific vector by liposome-mediated transfection Although electroporation-mediated DNA transfection is efficient for delivering vectors into prostate cells, 10 it may not be suitable for in vivo gene delivery. Alternatively, liposome-mediated gene delivery has been shown to be feasible for clinical trials and in vivo gene delivery. [13] [14] [15] Because virus is not involved, this method does not induce an immune response against reinjection of the vector. To achieve high levels of transfection, we used luciferase and GFP genes as reporters to test liposomes from several sources. We selected the Fu-GENE 6 liposome (Boehringer Mannheim), which yielded satisfactory levels of transfection. Using an optimized liposome-mediated gene delivery method, we transfected the prostate cancer cell line LNCaP and control cell lines derived from renal carcinoma, non-PSA-producing prostate cancer, and oral cancers. In the PSA-producing prostate cell line LNCaP, the activity of luciferase was 200-to 1000-fold higher than that in the renal cell line, R11, or in the non-PSA-producing prostate cell line, DU145 (Fig 1) . It was not surprising that our PSAR-PCPSA promoter does not work in the DU145 cell line, because this cell line does not express the endogenous PSA gene. The transcriptional activity and the tissue specificity obtained using liposome-mediated gene delivery were comparable with our previous results using electroporation as the means of gene delivery. 10 Our previous studies indicated that the activity of our prostate-specific promoter is androgen-dependent. Because the culture medium contains fetal bovine sera, which has low concentrations of androgen, the prostatespecific promoter demonstrated strong activity in the LNCaP cell line. With the addition to the medium of 50 nM DHT, luciferase expression increased by ϳ10-fold, whereas no significant increase in luciferase expression was seen in the controls (Fig 1A) . We compared the prostate-specific promoter side-by-side with the wellcharacterized CMV promoter, and the results indicated that the transcriptional activity of the prostate-specific promoter in the LNCaP cell line was ϳ10 -50% of the activity of the CMV promoter (Fig 1B) .
Eradication of the prostate cancer cells by the DTA expression vector
We inserted the modified thymidine kinase (TK) gene 16 into the prostate-specific vector. Although the modified TK gene should be at least 10-fold more potent than the wild-type TK gene, no significant cytopathic effects developed in the infected cells (data not shown). Alter-natively, we tested the toxic gene, DTA. The coding region of the amino terminal 193-aa residues was recovered by polymerase chain reaction, and start and termination codons were added to it. Because DTA can block protein synthesis, the effect of DTA gene expression can be evaluated by inhibition of luciferase gene expression if a luciferase gene is present. We cotransfected the DTA vector with the luciferase vector into the LNCaP cell line, and significant decreases in luciferase expression were demonstrated (Fig 2) , suggesting that DTA expression in the prostate cells blocks protein synthesis.
The DTA peptide inhibits protein synthesis by binding to elongation factor-2. Although the toxicity of DTA has been widely recognized, the cytopathic kinetics of DTA have not been well-characterized. Previously, diphtheria toxin (DT) was tested and strong pathogenic effects, including induction of cell apoptosis in prostate cancer cell culture, were demonstrated. 17 It would be interesting to know whether the A subunit of DT can also perform strong pathogenic effects in the transfected prostate cells. If only transfected cells are killed by expression of DTA, the liposome-mediated transfection method would be less efficient, because only a fraction of cells can be transfected. Therefore, most cancer cells could continue to grow and become resistant to the expression of DTA.
To evaluate transfection efficiencies and to characterize expression profiles in prostate cells, we constructed a plasmid vector containing the EGFP gene driven by the prostate-specific promoter. At 4 days posttransfection, Figure 1 . DNA from plasmids PSAR2.4k-PCPSA-P-Lux or TGF␤-P-Lux DNA (1.2 g) with or without 0.5-0.6 g of PSAR-PCPSA-P-DTA plasmid was used to transfect cultured cells. Luciferase assays were performed at 2 days posttransfection.
PANG: TARGETING AND ERADICATING PROSTATE CANCER CELLS
we counted positive cells under a UV microscope and found that 5-10% of LNCaP cells were transfected and had detectable levels of expression (Fig 3) . The CMV vector showed higher levels of expression in the transfected LNCaP cells, with 25-50% being EGFP-positive. In the control cell lines (R11, DU145, and Tu139), the expression of EGFP was also high when these cells were transfected by the CMV vector; however, no expression was detected in these cell lines when they were transfected by the prostate-specific vector.
If only 5-10% of LNCaP cells are transfected by the prostate-specific vector, we wanted to determine whether such a rate of transfection is sufficient for cancer cell eradication by the DTA gene vector. We transfected the LNCaP and control cell lines with the DTA vector, and significant pathogenic effects were demonstrated at 7-8 days posttransfection (Fig 4) . By day 8 posttransfection, Ͼ95% of cells died in the DTAtransfected LNCaP cell culture, compared with only ϳ10 -20% in the cultures transfected by other plasmids or by liposome only. However, because only 5-10% of transfected LNCaP cells actively express the DTA protein, cell death may not be attributable simply to the expression of the DTA gene. The majority of cell deaths could have been caused by a mechanism similar to the "bystander" effect seen with the expression of the TK gene. It is also possible that DTA or other toxic factors released from the transfected cells enter the nontransfected cells, causing cell death.
To determine whether this bystander effect was occurring, we set up cell cultures in transwell plates (purchased from Fisher, Pittsburgh, Penn). The LNCaP cell line, which was placed in the lower chambers, was transfected by the DTA vector; the R11 renal cell line or the DU145 cell line was cultured in the upper chambers of the plates after transfection of the LNCaP cells. Significant cell death occurred in the transfected LNCaP cell line, but not in the upper chamber cell cultures, suggesting that the cells were not killed by factors secreted from the transfected LNCaP cells. We also added conditioned medium from the DTA vector-transfected LNCaP cell culture to the untransfected LNCaP cell culture, but no significant cell death occurred. These results suggest that contact of the transfected cells with the untransfected cells may be required to induce the death of untransfected cells. Previous reports suggest that the inhibition of protein synthesis by proteins such as DT induces the machinery of cell apoptosis. [17] [18] [19] The pathogenic effects of DTA may involve a chain reaction, and inhibition of protein synthesis may activate that reaction chain.
DISCUSSION
For gene therapy with a "suicide" gene, accurate targeting of cancer cells is extremely important. One strategy is to use modified retroviral vectors to specifically deliver the toxic genes into the target cells. 20, 21 This approach is based on the specific binding of ligand molecules to matching cell surface receptors. The retroviral envelope protein is modified by truncation and fusion with appropriate ligand protein genes. However, this strategy is weakened by the possibility of nonspecific binding of the modified retroviral envelope protein to other cells. In addition, binding does not necessarily guarantee the entry of the vectors into the target cells. Cellular membrane proteins from the packaging cells are present in the envelope of the retroviral vector, and affect targeting accuracy. Another approach would be to use a tissuespecific promoter to obtain transcriptional targeting. To achieve tissue-specific expression, several promoters and enhancers have been tested. [2] [3] [4] To date, this approach has been impeded by "leaky expression" in inappropriate cells. The promoters that have been used for transcriptional targeting, such as the embryonic carcinoma antigen, tyrosinase, and ␣-fetoprotein, are not highly specific. For example, tyrosinase mRNA is also expressed in brain tissue. 22 Low levels of ␣-fetoprotein expression were also detected in normal liver tissue, suggesting that nonmalignant progenitor liver cells express ␣-fetoprotein. Therefore, the identification and development of more specific promoters is crucial.
The in vitro experimental results we have obtained with our PSA promoter are promising. Because the PSA protein is produced only in prostate cells, the promoter is tissue-specific. Although it is not specific to cancerous cells, treating prostate cancer patients with this promoter is unlikely to cause serious side effects, because the prostate gland is not an essential organ. This vector only targets prostate cancer cells that produce PSA mRNA, so it would not benefit those patients whose prostate cancer cells do not produce PSA mRNA. Our previous studies have indicated that cancer cells from some patients in advanced disease stages may not produce PSA mRNA. For these patients, a different prostate tissuespecific promoter would be needed.
Because DTA kills cells by apoptosis and the cells killed by apoptosis can induce an immune response specifically against cancer cells, 23,24 expression of the DTA gene in cancer cells will not only eradicate cancer cells by direct apoptosis and the bystander effect, but will also kill by indirect effects such as activation of the immune cancer cells effector cells against metastatic cancer cells. Tissue-specific pathogenic effects of the prostate-specific vector carrying the DTA gene. DNA transfections and cell culturing were carried out as described in Figure 2 . Culture medium was changed every 3 days. Trypan blue-stained cells were counted under a microscope. The percentage of surviving cells from the plates transfected by liposome only was set as 100%.
